Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18352553 | 0.94 | ZDHHC2 (0.48) | TAAR1NPC1RAB9AGAAZDHHC2 | |
| SCHEMBL18355254 | 0.92 | ZDHHC2 (0.51) | TAAR1NPC1RAB9AGAAZDHHC2 | |
| SCHEMBL18355438 | 0.90 | MAPT (0.51) | TAAR1NPC1RAB9AGAAZDHHC2 | |
| SCHEMBL18354880 | 0.87 | NPC1 (0.47) | TAAR1NPC1RAB9AGAAZDHHC2 | |
| SCHEMBL18352683 | 0.86 | ZDHHC2 (0.52) | TAAR1NPC1RAB9AGAAZDHHC2 | |
| SCHEMBL18364175 | 0.83 | MTNR1A (0.60) | RAB9AZDHHC2MTNR1AMTNR1BHCAR2 | |
| SCHEMBL16981272 | 0.83 | THRB (0.59) | TAAR1NPC1RAB9AGAAMTNR1A | |
| SCHEMBL18355458 | 0.83 | ZDHHC2 (0.53) | ZDHHC2 | |
| SCHEMBL16092878 | 0.82 | LMNA (0.65) | HCAR2 | |
| SCHEMBL18364190 | 0.81 | ZDHHC2 (0.50) | NPC1RAB9AGAAZDHHC2MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | TAAR1 4866/4885NPC1 2073/4885RAB9A 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.